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Abstract
Background: Non small cell lung cancer (NSCLC) is a leading cause of cancer death. We have shown previously that IL-12rb2
KO mice develop spontaneously lung adenocarcinomas or bronchioalveolar carcinomas. Aim of the study was to
investigate i) IL-12Rb2 expression in human primary lung adenocarcinomas and in their counterparts, i.e. normal bronchial
epithelial cells (NBEC), ii) the direct anti-tumor activity of IL-12 on lung adenocarcinoma cells in vitro and vivo, and the
mechanisms involved, and iii) IL-12 activity on NBEC.
Methodology/Principal Findings: Stage I lung adenocarcinomas showed significantly (P=0.012) higher frequency of IL-
12Rb2 expressing samples than stage II/III tumors. IL-12 treatment of IL-12R
+ neoplastic cells isolated from primary
adenocarcinoma (n=6) inhibited angiogenesis in vitro through down-regulation of different pro-angiogenic genes (e.g. IL-6,
VEGF-C, VEGF-D, and laminin-5), as assessed by chorioallantoic membrane (CAM) assay and PCR array. In order to perform in
vivo studies, the Calu6 NSCLC cell line was transfected with the IL-12RB2 containing plasmid (Calu6/b2). Similar to that
observed in primary tumors, IL-12 treatment of Calu6/b2
+ cells inhibited angiogenesis in vitro. Tumors formed by Calu6/b2
cells in SCID/NOD mice, inoculated subcutaneously or orthotopically, were significantly smaller following IL-12 vs PBS
treatment due to inhibition of angiogenesis, and of IL-6 and VEGF-C production. Explanted tumors were studied by
histology, immuno-histochemistry and PCR array. NBEC cells were isolated and cultured from lung specimens of non
neoplastic origin. NBEC expressed IL-12R and released constitutively tumor promoting cytokines (e.g. IL-6 and CCL2).
Treatment of NBEC with IL-12 down-regulated production of these cytokines.
Conclusions: This study demonstrates that IL-12 inhibits directly the growth of human lung adenocarcinoma and targets
the adjacent NBEC. These novel anti-tumor activities of IL-12 add to the well known immune-modulatory properties of the
cytokine and may provide a rational basis for the development of a clinical trial.
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Introduction
IL-12 is a cytokine that exerts potent anti-tumor activity
through a combination of immunostimulatory and anti-angiogenic
mechanisms [1–3]. The latter are related to induction of IFN-c,
which in turn triggers the release of the anti-angiogenic
chemokines CXCL9, CXCL10 and CXCL11. In addition, IL-
12 down-regulates the production of the pro-angiogenic molecules
VEGF and FGF-2 [4–7]. The IL-12 receptor (R) is comprised of
two subunits, i.e. the ubiquitous IL-12Rb1 and IL-12Rb2 that
shows a restricted distribution [8].
We [1,9] have previously shown that the IL-12RB2 gene,
encoding the IL-12R chain essential for IL-12 signal transduction,
functions as a tumor suppressor in human neoplastic B cells from
various chronic lymphoproliferative disorders and acute lympho-
blastic leukemia. We [10] have also demonstrated that IL-12rb2
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infiltrates, systemic IL-6 up-regulation and in the second year of
life, lung adenocarcinomas and brochioalveolar carcinomas,
possibly in relation to IL-6 over-expression [10]. IL-6 promotes
lung cancer growth and metastasis [11,13] and we [10] have
demonstrated that IL-12 dampens IL-6 production in mouse
splenocytes.
Taken together, the results obtained with IL-12rb2 deficient
mice indicated that IL-12 acts as a gatekeeper from the
spontaneous development of lung cancer. By inference, IL-12
may represent a novel therapeutic agent against established
human lung carcinomas.
Lung cancer is a leading cause of cancer death worldwide [14].
The large majority of cases are non-small-cell lung cancers
(NSCLC) [14]. The distribution of NSCLC histologic subtypes has
changed over the past 20 years, with decreased incidence of
squamous-cell carcinoma and increased frequency of adenocarci-
noma, now accounting for 40% of all lung cancer diagnoses [15].
NSCLC prognosis is still grim [16] and novel therapeutic
approaches are warranted.
With this background, we have investigated IL-12R expression
and function in human primary lung adenocarcinomas and the
direct anti-tumor activity of IL-12 on NSCLC cells in vitro and in
vivo, unraveling the molecular mechanisms involved. We have also
addressed the question of whether normal bronchial epithelial cells
(NBEC), that represent potential counterparts of NSCLC cells,
express functional IL-12R.
Results
Expression of IL-12Rb2 in human lung adenocarcinomas
We first investigated the expression of the IL-12Rb2 in lung
tissue samples from seventy lung adenocarcinoma patients.
Immunohistochemical analyses revealed that 29/70 lung
adenocarcinomas (41.4%), 22/49 of which were adenocarcinomas
with bronchioloalveolar features (ADBF), 4/13 pure bronchio-
loalveolar carcinomas (BAC) and 3/8 conventional adenocarci-
nomas (ADC) [15], did not express IL-12Rb2 (Table 1 and
Fig. 1A, panel b). IL-12Rb2 was expressed by some of the cells
forming the neoplastic glands (inset in panel b). Normal lung peri-
tumoral tissue, i.e. alveolar (Fig. 1A, panel c) and bronchiolar (not
shown) epithelium, expressed IL-12Rb2.
Thirty/70 adenocarcinomas (42.9%), 21/49 of which were
ADBF, 2/8 ADC and 7/13 BAC, were positive for IL-12Rb2
expression (Table 1 and Fig. 1A, d). 6/70 cases (8.6%), 4/49 of
which were ADBF, 1/8 ADC and 1/13 BAC, were weakly
positive, while 5 cases (7.1%), 2/49 of which were ADBF, 2/8
ADC and 1/13 BAC, were mixed (Table 1).
When only IL-12Rb2 positive and negative lung adenocarci-
nomas according to the score used were analyzed, IL-12Rb2
positive tumors were significantly more numerous in stage I than
stage II/III patients (P=0.012, Fisher’s exact test).
IL-12 inhibits the pro-angiogenic activity of human
primary lung adenocarcinoma cells through down-
regulation of multiple pro-angiogenic genes
Lung cancers are known to release several pro-angiogenic
factors and angiogenesis inhibition represents a promising
therapeutic target [17]. We then asked whether the angiogenic
potential of primary ADC cells was affected by IL-12, similarly to
that observed in other tumor models [1,18,19]. We therefore
incubated IL-12Rb2 expressing neoplastic cells from six lung ADC
patients with hrIL-12 or medium alone and tested the angiogenic
activity of culture supernatants in the chorio-allantoic membrane
(CAM) assay. CAM treated with sponges loaded with VEGF
(positive control) or with supernatants from primary ADC cells
were surrounded by allantoic vessels developing radially towards
the implant in a ‘spoked-wheel’ pattern. In the representative
experiment shown in Fig. 1B, left panel, the mean number of
vessels formed in the presence of supernatant from ADC cells was
2463, while that formed in the presence of VEGF was 2865 (not
shown). No vascular reaction was detected around the sponges
upon exposure to human recombinant (hr)IL12 diluted in medium
at the same final concentration used to treat tumor cells (mean
number of vessels=763 in the presence or absence of hrIL-12,
not shown). When the supernatants from hrIL-12 treated tumor
cells from the same ADC patients were tested in the CAM assay, a
significant (P,0.001) reduction of the angiogenic response was
appreciable (mean number of vessels=1362) (Figure 1B, right
panel), as compared to positive control. Similar results with the
same statistical significance were obtained when the five remaining
primary ADC cell suspensions were tested. Next, we investigated
expression of pro-angiogenic and anti-angiogenic genes in primary
ADC cells incubated with IL-12 or medium. Neoplastic cells from
three different ADC patients were cultured for 48h in the presence
or absence of hrIL-12. RNA was extracted from cultured cells,
reverse transcribed and tested by PCR Array.
Fig. 1C shows the pooled results from the 3 samples analyzed.
IL-12 treatment down-regulated significantly (P,0.001) mRNA of
the pro-angiogenic factors CCL2, endoglin, HIF-1a, COX1/
COX3, VEGF-C and –D, laminin-5, Ephrin-B2 and IL-6.
Taken together, these findings demonstrated that IL-12R was
functional in human primary ADC cells and that IL-12 treatment
damped their pro-angiogenic activity.
IL-12RB2 expression in human NSCLC cell lines
We next developed a pre-clinical model suitable to investigate
the function of IL-12R in human lung adenocarcinoma. To this
end, we first screened a panel of human NSCLC cell lines and
found that none of them expressed IL-12RB2 mRNA (Fig. 2A)
due to methylation of a CpG island in exon 1 (not shown), as
previously demonstrated for different malignant cells [1,9,20].
Therefore, the Calu6 cell line was stably transfected with an IL-
12Rb2 containing plasmid or with the empty vector containing
plasmid (control). From now onwards Calu6 cells transfected with
IL-12Rb2 containing plasmid will be referred to as Calu6/b2.
Calu6/b2 cells expressed IL-12RB2 transcript (Fig. 2A) and
protein (Fig. 2B, left panel). Incubation of Calu6/b2 cells with
hrIL-12 caused i) down-regulation of constitutive IL-6 production
(P=0.002), as assessed by flow cytometry (Fig. 2B, right panel) and
ii) significant (P=0.001) reduction of angiogenic activity in culture
supernatants, as assessed by CAM assay (IL-12: mean number of
vessels=1563, medium: mean number of vessels=2764)
(Fig. 2C, upper panels).
IL-12 did not modulate production of angiogenic factors or IL-6
by empty vector transfected Calu6 cells (not shown).
Apoptosis and proliferation were not affected by IL-12
treatment (not shown).
These results are consistent with those obtained with human
primary ADC cells, thus indicating that the Calu6/b2 cells display
functional similarities to the primary ADC cells and represent an
useful model for in vivo studies.
IL-6 is a major angiogenic factor involved in vessel
formation derived from NSCLC
In order to prove unambiguously that IL-6 and VEGF-C were
the major angiogenic factors produced by human NSCLC, we
tested the angiogenic activity of Calu6/b2 cell supernatants
Lung Adenocarcinoma and IL-12
PLoS ONE | www.plosone.org 2 July 2009 | Volume 4 | Issue 7 | e6119Figure 1. IL-12Rb2 expression and function in human lung adenocarcinoma. 1A. Histological features and IL-12Rb2 expression in human
bronchioloalveolar lung carcinomas. Non-mucinous bronchioloalveolar carcinoma typically shows columnar neoplastic cells growing along the
alveolar septa (a). In 41.4% of adenocarcinomas, neoplastic cells lack IL12Rb2 expression (b), though a few may sometimes retain it (inset in b). By
contrast, alveoli unaffected by malignant process express IL-12Rb2 (c), as observed in the remaining tumors (d). (6400). 1B. Angiogenic activity of
supernatants from one representative lung ADC sample cultured in the presence or absence of hrIL12. CAM treated with sponges loaded with
supernatant from the untreated cells were surrounded by allantoic vessels developing radially towards the implant in a ‘spoked-wheel’ pattern (left
panel). When supernatants from hrIL-12 treated lung ADC sample was tested, a significant reduction (P=0.001) of the angiogenic response was
appreciable (right panel). These experiments were repeated three times. Original magnification: 650. 1C. Pooled results from human angiogenesis
PCR array performed in three lung ADC samples cultured in the presence or absence of hrIL-12 are shown. Histogram shows fold expression changes
of genes in primary samples treated with hrIL-12 vs medium.
doi:10.1371/journal.pone.0006119.g001
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IL-6. As shown in Figure 2D, neutralization of IL-6 (left panel) but
not of VEGF-C (right panel) inhibited significantly (P,0.001) the
angiogenic potential of the Calu6/b2 cells (medium, mean
number of vessels=2463; anti IL-6, mean number of ves-
sels=1063; anti VEGF-C mean number of vessels=2064).
These results demonstrated unambiguously that IL-6, but not
VEGF-C, plays a key role in inducing new vessel formation
derived from NSCLC cells. It is of note that VEGF-C is involved
in tumor lymphangiogenesis rather than in tumor angiogenesis
[21–22] and the CAM assay allows to evaluate blood vessel but not
lymphatic vessel formation.
IL-12 inhibits tumorigenicity of Calu6/b2 cells in SCID-
NOD mice
Tumorigenicity of Calu6/b2 cells or Calu6 cells transfected
with empty vector was next investigated. SCID-NOD mice
receiving intrapulmonary inoculation of Calu6/b2 cells (orthotop-
ic model) and treated with hrIL-12 developed tumors significantly
smaller (P,0.0001) than mice inoculated with the same cells and
treated with PBS (n=7 for both groups; IL-12 treated, median
volume 18.55 mm
3; range 1–32.8 mm
3. PBS treated, median
volume 34.44 mm
3; range 24.7–46.62 mm
3) (Figure 3A, left
panel).
Mice injected subcutaneously with Calu6/b2 cells and treated
with hrIL-12 developed tumors significantly smaller (P=0.0001)
than mice treated with PBS (n=12 for both groups; IL-12 treated,
median volume 131 mm
3; range 1–186 mm
3. PBS treated,
median volume 261 mm
3; range 147–3069 mm
3) (Figure 3A,
right panel).
Empty vector transfected Calu6 cells and Calu6/b2 cells
produced tumors of similar size in mice treated with PBS (not
shown). Furthermore, tumors formed by empty vector transfected
Calu6 cells in hrIL-12 treated mice were of similar size to those
formed by Calu6/b2 cells in PBS-treated mice independent of the
subcutaneous or orthotopic models tested (Fig. 3A, left and right
panels).
Tumors formed by Calu6/b2 cells subcutaneously or orthopi-
cally in PBS treated mice (Fig. 3B, panels a and e, respectively)
were composed of nests of undifferentiated, pleomorphic and
proliferating cells invading the underlying muscle layers and
supplied by a distinct network of mature microvessels (Fig. 3B,
panels b and f, respectively). In contrast, subcutaneous or
Table 1. Clinicopathological Characteristics of 70 Patients with Lung Adenocarcinoma and IL-12Rb2 Expression Profiles of their
Tumors
TNM IL-12Rb2 Immunostaining *
Negative (n29) Positive (n30) Weakly Positive (n6) Mixed (n5)
Age (range 31–83)
Gender
Male (54) 24 22 5 3
Female (16) 5 8 1 2
Histological type
ADBF (49) 22 (45%) 21(43%) 4 (8%) 2 (4%)
BAC (13) 4 (31%) 7 (54%) 1 (7.5%) 1 (7.5%)
ADC (8) 3 (37.5%) 2 (25%) 1 (12.5%) 2 (25%)
Tumor Size
T1 (42) 17 19 4 2
T2 (20) 7 9 2 2
T3 (8) 5 2 1
Node Status
N0 (50) 18 27 2 3
N1 (18) 8 4 4 2
N2 (2) 2
Metastases
M0 (70) ND ND ND ND
Stage
IA (33) 12 (36%) 17 (52%) 2 (6%) 2 (6%)
IB (12) 3 (25%) 8 (67%) 1 (8%)
IIA (8) 4 (50%) 2 (25%) 2 (25%)
IIB (12) 6 (50%) 3 (25%) 2 (17%) 1 (8%)
IIIA (5) 4 (80%) 1 (20%)
*IL-12Rb2 immunostaining was scored as negative, positive, weakly positive or mixed as described in methods.
ND: not detected.
ADBF: adenocarcinomas with bronchioloalveolar features.
BAC: bronchioloalveolar carcinomas.
ADC: adenocarcinomas.
doi:10.1371/journal.pone.0006119.t001
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PLoS ONE | www.plosone.org 4 July 2009 | Volume 4 | Issue 7 | e6119Figure 2. IL-12Rb2 expression and function in human NSCLC cell lines. 2A. IL-12RB2 expression in NSCLC cell lines, as assessed by RT-PCR.
From left to right: MW=molecular weight; NC=negative control (Raji cell line); PC=positive control (total tonsil B cells); different NSCLC cell lines
(Colo699, Calu6, Calu1, A549, SK-MES-1, GLC82 and Calu6/b2 cells) are shown. 2B. Left panel. IL-12Rb2 protein expression in Calu6/b2 cells, as
assessed by flow cytometry. Open profile: IL-12Rb2 staining; dark profile: isotype matched antibody staining. Right panel. IL-6 intracellular staining
in Calu6/b2 cells cultured with medium or hrIL-12 for 48 h, as assessed by flow cytometry. Open profile: IL-6 staining in cells cultured with medium;
dark profile: isotype matched antibody staining, dashed line: IL-6 staining in cells cultured with IL-12. 2C. Angiogenic activity of supernatants from
Calu6/b2 cells cultured with medium alone or hrIL12. CAM treated with sponges loaded with supernatant from the untreated cells were surrounded
by allantoic vessels developing radially towards the implant in a ‘spoked-wheel’ pattern (upper left panel). When supernatants from hrIL-12treated
Calu6/b2 cells was tested, a significant reduction (P=0.001) of the angiogenic response was appreciable (upper right panel). Lower panels show the
angiogenic activity of Calu6/b2 cells in the presence of an anti-IL-6 mAb (left panel) or of an anti-VEGF-C mAb (right panel). These experiments were
repeated three times. Original magnification: 650.
doi:10.1371/journal.pone.0006119.g002
Lung Adenocarcinoma and IL-12
PLoS ONE | www.plosone.org 5 July 2009 | Volume 4 | Issue 7 | e6119Figure 3. Anti-tumor activity of IL-12 on NSCLC in vivo. 3A. Volume of tumors grown after Calu6/b2 cell inoculation orthotopically (left panel)
or subcutaneously (right panel) in PBS and hrIL-12 treated animals. Animals injected orthotopically were sacrificed after 23 days, those injected
subcutaneously after 14 days. Volume of tumors grown after inoculation orthotopically (left panel) or subcutaneously (right panel) of Calu6 cell
transfected with the empty vector hrIL-12 treated animals was also shown (empty vector+IL12). The differences in size between tumors removed
from PBS and hrIL-12 treated mice were evaluated by Mann-Whitney U test. Boxes indicate values between the 25
th and 75
th percentiles, whisker lines
represent highest and lowest values for each group. Horizontal lines represent median values. 3B. Tumors (developed after s.c injection) injected
subcutaneously with Calu6/b2 cells in PBS-treated SCID/NOD mice are mostly formed of nests of undifferentiated, pleomorphic and proliferating cells
Lung Adenocarcinoma and IL-12
PLoS ONE | www.plosone.org 6 July 2009 | Volume 4 | Issue 7 | e6119orthotopic tumors from hrIL-12 treated mice showed large areas
of ischemic-hemorrhagic necrosis (Fig. 3B, panel c and g,
respectively) associated with defective microvascular architecture
(Fig. 3B, panels d and h, respectively).
In vivo modulation of the expression of angiogenesis related
genes was next investigated by PCR array comparing three tumors
from IL-12 treated mice to three tumors from PBS treated mice.
IL-12 treatment downregulated significantly (P,0.001) mRNA of
the pro-angiogenic factors VEGF-C, VEGFR-2, Leptin, PROK2,
COX1/COX3, and thrombospondin 2, whereas up-regulated
mRNA of the angiogenesis inhibitors IFN-a and – b (P,0.001).
The transcripts of the pro-angiogenic AKT1, CD13, Endoglin,
FGF-1, PGF-2 and UPA genes were also up-regulated in these
cells (P,0.001) (Fig. 3C).
Finally, tumors from PBS-treated mice expressed VEGF-C
(Figure 3D, panel a) and IL-6 (Figure 3D, panel c), as assessed by
immunohistochemistry. Expression of VEGF-C and IL-6 was
strongly reduced (Figure 3D, panels b and d, respectively) in
tumors from hrIL-12 treated mice.
Expression and function of IL-12Rb2 in normal human
bronchial epithelial cells
Since alveolar and bronchiolar epithelium surrounding the
neoplastic tissue from lung adenocarcinoma patients expressed IL-
12Rb2 (Fig. 1A, panel c), we next investigated whether IL-12Rb2
was expressed and functional in NBEC from patients undergoing
lung resection for non-malignant disorders. These cells were
expanded in vitro under conditions that allow to preserve
functional features similar to those of primary bronchial epithelial
cells [23,24].
Figure 4 shows expression of IL-12RB2 mRNA (panel A) and
protein (panel B) in cultured bronchial epithelial cells from 3
different donors. These cells also expressed the ubiquitous IL-
12RB1 mRNA and protein (not shown).
Our [25,26] previous studies demonstrated that inflammatory
cytokines affected transepithelial ion transport. In particular, we
showed that 24–48 h treatment with IFN-c caused marked
changes in Na
+,C l
2, and fluid transport in the bronchial
epithelium, possibly by altering the activity/expression of the
corresponding ion channels [25]. In order to investigate whether
also IL-12 influenced the ion transport properties of NBEC, the
latter cells were exposed for 24 h to IL-12 and tested for ion
transport.
Cells were sequentially incubated with amiloride to inhibit the
epithelial sodium channel (ENaC), the cAMP-elevating agent
forskolin to activate cystic fibrosis transmembrane conductance
regulator (CFTR), and uridine tri-phosphate (UTP) to trigger the
activation of Ca
2+-dependent Cl
2 channels [25,26]. No significant
differences in the changes elicited by the three pharmacological
agents between control and IL-12 treated cells were detected
(Fig. 4C). Indeed, the amiloride-sensitive current, reflecting the
activity of ENaC, was 20.562.4 mA/cm
2 (n=3) for control and
17.863.6 mA/cm
2 (n=3) for treated cells. Similarly, the cAMP-
activated current was not altered: 8.764.5 and 7.164.1 mA/cm
2
for control and treated cells, respectively. The lack of effect on
cAMP-activated Cl
2 transport, i.e. on CFTR activity, was also
indicated by the similar extent of current change produced by
CFTRinh-172, a selective inhibitor of the CFTR channel (Fig. 4C).
Finally, the effect of UTP, measured at the peak, was
4.261.4 mA/cm
2 (n=3) for untreated cells and 5.960.5 mA/
cm
2 (n=3) for IL-12 treated cells.
Next, three different NBEC populations were cultured for 48 h
with or without IL-12 and supernatants tested for the presence of a
panel of cytokines and chemokines. As shown in Figure 4D, IL-12
reduced significantly the constitutive release of the pro-angiogenic
factors IL-6 (P=0.0049), IL-8 (P=0.0071) and FGF-b
(P=0.0231) and of the pro-inflammatory molecules GM-CSF
(P=0.0028), CCL2/MCP-1 (P=0.0002) and CCL5/RANTES
(P=0.0108). Finally, IL-12 down-regulated the release of the anti-
angiogenic molecule CXCL10/IP-10 (P,0.0001).
Discussion
In this study, we have addressed the role of the IL-12/IL-12R
system in human lung ADC based upon our previous finding that
IL-12rb2 KO mice, which produce but cannot utilize IL-12,
develop spontaneously systemic IL-6 overproduction and lung
ADC or bronchoalveolar carcinoma [10]. Other studies from our
group lend cogent support to the notion that IL-12 acts a negative
regulator of the growth of both hematopoietic and non-
hematopoietic tumors [1,9,10,18,19].
We first investigated IL-12Rb2 expression on human primary
ADC using immunohistochemistry on a large panel of ADC tissue
sections. These studies showed that stage I tumors displayed a
significantly higher frequency of IL-12Rb2
+ samples than stage II/
III tumors, suggesting that IL-12Rb2 down-regulation may be a
tumor escape mechanism. Six primary ADC cell suspensions
selected on the ground of high level IL-12Rb2 expression were
next cultured with IL-12 and tested for proliferation, survival and
production of angiogenic factors in the CAM assay. These
experiments demonstrated unambiguously that the IL-12R
expressed by primary ADC cells was functional since their
incubation with IL-12 strongly damped angiogenic activity while
unaffecting cell proliferation or survival. PCR array experiments
with primary ADC cell fractions demonstrated that IL-12 induced
predominantly a potent down-regulation of the expression of pro-
angiogenic genes (e.g. IL-6, CCL-2 and VEGF). In this respect,
supernatants from Calu6/b2 cells incubated with a neutralizing
antibody to IL-6 showed a significantly decreased pro-angiogenic
activity in the CAM assay, indicating that IL-6 was a major
angiogenic factor for NSCLC. In contrast, neutralization of
VEGF-C did not affect the angiogenic activity of Calu6/b2 cell
supernatants, a finding possibly related to the key role of this
molecule in lymphangiogenesis, that cannot be evaluated by the
CAM assay.
In order to investigate the in vivo effects of IL-12 on human
ADC cells, we developed an experimental model based upon the
Calu6 cell line transfected with an IL-12Rb2 cDNA containing
(mitotic (figures) features indicated by arrows) rapidly infiltrating the underlying muscle layers (arrowheads) (a), and supplied by a distinct microvessel
network, as assessed by laminin staining (b). In hrIL-12 treated mice, tumor histology is altered by the appearance of large areas of ischemic-
hemorrhagic necrosis (N) (c) associated with defective microvascular architecture (d) (6400). Orthotopical injection of Calu6/b2 cells gave rise, in PBS-
treated mice, to tumors with istopathological features (e) similar to those of subcutaneously developed tumors (a) and supplied by a well developed
microvascular network (f). As observed in subcutaneous tumors, in orthotopic tumors as well hrIL-12 treatment induced wide necrosis (g) and severe
microvascular alterations (h) (6400). 3C. Human Angiogenesis PCR Array on tumors explanted from hrIL-12 vs PBS treated animals 23 days after
orthotopic inoculation of Calu6/b2 cells. Histogram shows fold expression changes of genes in tumors from hrIL-12 vs PBC treated mice. 3D. Tumors
from PBS-treated mice express VEGF-C (a) and IL-6 (c). Expression of VEGF-C and IL-6 is strongly reduced (b and d, respectively) in tumors from hrIL-12
treated mice. (6400).
doi:10.1371/journal.pone.0006119.g003
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PLoS ONE | www.plosone.org 7 July 2009 | Volume 4 | Issue 7 | e6119Figure 4. IL-12Rb2 expression and function in normal bronchial epithelial cells. 4A. IL-12RB2 expression in human primary bronchial
epithelial cells, as assessed by RT-PCR. From left to right: MW=molecular weight; NC=negative control (Raji cell line); three different NBEC cultures
(NBEC #1, #2 and #3) are shown. 4B. IL-12Rb2 surface expression in human NBEC, as assessed by flow cytometry. Open profile: IL-12Rb2 staining;
dark profile: isotype matched mAb staining. 4C. Short circuit current recordings in normal bronchial epithelial cells. The figure depicts two
representative experiments from control (top) and IL-12 treated (bottom) epithelia showing responses to amiloride (10 mM, apical), forskolin (20 mM,
apical and basolateral), UTP (100 mM, apical), and CFTRinh-172 (10 mM, apical). 4D. Cytokine release by human NBEC, as assessed by Bio-Plex Assay.
Pooled results from supernatants of three different bronchial epithelial cell suspensions are shown. IL-12 treatment reduced significantly the release
of IL-6 (P=0.0049), IL-8 (P=0.0071), FGF-b (P=0.0231), GM-CSF (P=0.0028), IP-10 (P,0.0001), MCP-1 (P=0.0002) and RANTES (P=0.0108).
doi:10.1371/journal.pone.0006119.g004
Lung Adenocarcinoma and IL-12
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decreased significantly IL-6 production and the angiogenic
potential of Calu6/b2 cells in vitro, while unaffecting proliferation
and apoptosis. These results indicated that Calu6/b2 cells
represented a model mimicking primary ADC cells and were
therefore suitable for in vivo experiments.
Therefore, we next investigated the in vivo effects of hrIL-12 on
the tumorigenicity of Calu6/b2 cells injected orthotopically or
subcutaneously in SCID/NOD mice. These animal models allow
to assess the direct effects of human IL-12, that is species-specific
and inactive in the mouse, on human tumor cells in the absence of
immune response [8]. Moreover, the orthotopic model mimicks
closely the pattern of growth of human lung adenocarcinoma and
provides insights of translational relevance.
These experiments demonstrated that tumors formed by
Calu6/b2 cells in SCID/NOD mice, either orthotopically or
subcutaneously, were significantly smaller following hrIL-12 vs
PBS treatment and that the IL-12 mediated anti-tumor activity
was primarily due to inhibition of angiogenesis resulting from a
complex modulation of the expression of anti-angiogenic (e.g.
IFN-a and –b) and pro-angiogenic (e.g. VEGF-C, VEGFR-2,
Leptin, PROK2, COX1/COX3, thrombospondin 2) genes. In
addition, IL-12 damped in vivo expression of VEGF-C and IL-6
proteins [11,27,28].
High IL-6 levels have been detected in serum from lung
adenocarcinoma patients and correlated with poor prognosis.
Furthermore, IL-6 has been implicated in autocrine loops
promoting tumor growth. These observations have led to conclude
that IL-6 plays an oncogenic role in NSCLC [29].
Our results together with those from other groups indicate that
IL-12 can target the tumor microenvironment by acting at
different and complementary levels. Thus, we show that IL-12
inhibits directly human NSCLC growth, and others [30] have
demonstrated in mouse models that IL-12 alters the functional
profile of tumor associated macrophages (TAM) by rapidly
reducing production of IL-10, MCP-1/CCL2, migration inhibi-
tory factor and TGF-b1, and increasing release of TNF, IL-15 and
IL-18. The ability of IL-12 to reverse TAM function may
contribute to amplify subsequent tumor lysis by cytotoxic effector
cells [30].
In this connection, we investigated the functionality of IL-12R
on in vitro expanded NBEC since immunohistochemical studies
disclosed IL-12Rb2 expression in NBEC surrounding the tumor.
IL-12 treatment of NBEC reduced significantly their ability to
release some cytokines/chemokines that have been shown to be
involved in NSCLC angiogenesis, progression and spreading [31–
36] such as, for example, MCP-1/CCL2 and IL-6 [37]. MCP-1/
CCL2 recruits TAM to the tumor site, and these cells release IL-6
and contribute to tumor stroma formation and angiogenesis [37].
On the other hand, IL-12 down-regulated NBEC production of
CXCL10, pointing to the complex modulation of angiogenesis-
related gene expression operated by the cytokine.
The results here obtained using in vitro cultured NBEC
conceivably apply also to primary NBEC since cells expanded
under our conditions retain functional characteristics similar to
those of primary cells. IL-12 mediated down-regulation of the
release of tumor promoting cytokines by NBEC may suggest that i)
peritumoral NBEC contribute to support lung adenocarcinoma
growth [38] and consequently ii) NBEC represent an additional
IL-12 target.
This study demonstrates that IL-12R expressed on the surface
of tumor cells and of the adjacent NBEC may represent a novel
therapeutic target for human lung adenocarcinoma. In principle,
IL-12 might be administered to lung adenocarcinoma patients
(selected on the ground of IL-12Rb2 expression in tumor cells) as
tumor-targeted formulations to act directly on the tumor
microenvironment [39] or systemically to take advantage of the
immunomodulatory activity of the cytokine [3]. The feasibility of
this potential therapeutic approach appears to be reasonable since
IL-12 has been tested as investigational drug in patients with
different malignancies [30,40,41] and its safety and pharmacoki-
netics profiles are well known.
Materials and Methods
Patients and histological studies
Written informed consent was obtained from all patients and
the study was approved by the S.S. Annunziata Hospital’s Ethical
Committee, Chieti, Italy. This investigation conformed with the
principles of Helsinki Declaration.
Lung adenocarcinoma tissues were obtained at diagnosis from
seventy consecutive untreated patients with resectable tumors and
processed in the Anatomical Pathology Department of the "SS.
Annunziata" Hospital. Tumor stage was determined according to
the Tumor-Node-Metastasis (TNM) staging system [42]. Tumor
histology was classified according to the WHO criteria [15].
Paraffin embedded tissues were processed as reported [19] and
stained with the following anti-human antibodies: anti-IL-12Rb2
(goat polyclonal, Santa Cruz, Santa Cruz, CA, USA), anti-
Laminin mAb (Biogenex, San Ramon, CA, USA), anti-VEGF-C
mAb (Zymed, San Francisco, CA, USA), or anti- IL6 (rabbit
polyclonal, Abcam, Cambridge, UK). IL-12Rb2 immunostaining
was defined as ‘‘positive’’ when $70% of the tumor cells stained
moderately to strongly; ‘‘weakly positive’’ when $70% stained
weakly; ‘‘mixed’’ when ,70%, but $40% were stained;
‘‘negative’’ when ,40% were stained. Immunostained sections
were examined independently by two pathologists with very good
agreement [k value=0.85 according to ref.[43]].
Primary adenocarcinoma cells were isolated by mincing of fresh
tumor fragments obtained at surgery and containing at least 80%
malignant cells, as assessed by morphological analysis. Cell
suspensions obtained from four stage I and 2 stage II tumors
were selected for further studies following cytofluorimetric
demonstration of IL-12Rb2 expression on higher than 70% of
malignant cells. All patients (four males, two females, age range
55–70) were untreated at the time of surgical intervention.
Flow cytometry and apoptosis assay
Cells were stained with anti-IL-12RB2 goat antiserum (Santa
Cruz) or anti-IL-6 mAb (Caltag, Burlingame, CA) using the BD
Cytofix/Cytoperm
TM fixation/permeabilization kit (BD Biosci-
ences) and analyzed by flow cytometry [18]. Apoptosis was
assessed by flow cytometry using an annexin V-FITC apoptosis kit
(Immunostep, Salamanca, Spain).
CAM assay
The CAM assay was performed as described [44,45]. CAM
were loaded with: 1 ml PBS (negative control); 1 ml PBS with 250
ng VEGF (R&D Systems, Abingdon, UK) as positive control; 1 ml
of medium from Calu6/b2 cells cultured 48 h with or without
hrIL-12; 1 ml of medium from empty vector transfected Calu6 cells
cultured 48 h with or without hrIL-12; 1 ml of medium from
primary ADC cells cultured 48 h with or without hrIL-12, 1 mlo f
medium containing hrIL-12. All supernatants were tested in
quadruplicate and means6SD were calculated. On day 12, the
angiogenic response was evaluated by image analyzer as number
of vessels converging toward the sponges [44,45].
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loaded with 1 ml of medium from Calu6/b2 cells alone or
containing 50 ng of an anti-human IL-6 mAb (Santa Cruz
Biotechnology, Santa Cruz, USA) or of an anti-human VEGF-C
mAb (Santa Cruz Biotechnology).
PCR-Array
RNA was extracted using TRIZOLH from Invitrogen (Carls-
bad, CA, USA) and reverse transcribed by the ReactionReady
TM
First Strand cDNA Synthesis kit (SuperArray Bioscience Corpo-
ration). Contaminant genomic DNA was removed by Dnase
treatment using Rneasy Micro Kit (Qiagen GmbH) before starting
PCR-Array procedure.
Human Angiogenesis RT
2 Profiler
TM PCR Array and RT
2
Real-Time
TM SyBR Green/ROX PCR Mix were purchased from
SuperArray Bioscience Corporation. PCR was performed as
described [18,19]
Cell culture and transfection
Human NSCLC A549, Calu-1, Calu-6, Colo699, GLC82, SK-
MES-1 and SK-LU-1 cell lines or primary ADC cells were
cultured in RPMI 1640 medium (Seromed-BiochromKG, Berlin,
Germany) with 10% FCS (Seromed) for the indicated times.
Human recombinant hrIL-12 (20 ng/ml) was from Wyeth,
Cambridge, MA. Based upon a preliminary screening of cell line
tumorigenicity in the orthotopic model (see below), Calu6 cells
were selected to be transfected with IL-12RB2/pEGFP-N1 or
empty vector by electroporation. Stable transfectants were selected
and checked for IL-12RB2 gene and protein expression [1].
Methylation assay
DNA was extracted using GenElute DNA miniprep kit from
Sigma and the methylation status of the target sequence was
assessed by Methylation Specific PCR [1].
Mice studies
Five- to 7-week-old female SCID-NOD mice (Harlan Labora-
tories, Udine, Italy) were housed in pathogen-free conditions. All
procedures were performed according to the National and
International current regulations (D.l.vo 27/01/1992, n.116,
European Economic Community Council Directive 86/609,
OJL 358, Dec. 1, 1987).
Two groups of seven animals each were injected subcuta-
neously with 3610
6 empty vector transfected Calu6 cells. Two
additional groups of seven mice each were injected subcuta-
neously with 3610
6 Calu6/b2 cells. One group of mice for
each of the above combinations was treated with 3 weekly
doses of hrIL-12 subcutaneously (1 mg/mouse/dose) starting
from 6 h after injection of tumor cells. The other group of
mice from each combination was injected with PBS according
to the same time schedule. Fourteen days after tumor cell
inoculation, mice were sacrificed and tumor volume measured
as described [1].
In another series of experiments, two groups of twelve mice
each were anesthetized with a mixture of Ketamine (80 mg/kg
body weight) and Xylazine (5 mg/kg body weight) IP. The skin
overlying the left chest wall in the mid-axillary line was prepped
with tricotomy, disinfection. Incision was performed (3 mm) and
the underlying chest wall and intercostal spaces were visualized.
1.5610
5 Calu6/2 cells were injected into the left lateral thorax, at
the lateral dorsal axillary line. After tumor injection, the mice were
turned to the left lateral decubitus position and observed for 45 to
60 min until fully recovered. No anesthesia or surgery-related
deaths occurred. Two additional groups of twelve mice were
injected orthotopically with 1.5610
5 empty vector transfected
Calu6 cells. One group of mice from each of the above
combinations was treated with 3 weekly doses of hrIL-12
intravenously (1 mg/mouse/dose) or PBS starting from 6 h after
injection of tumor cells. Animals were sacrificed twenty three days
after tumor inoculation.
Primary culture of bronchial epithelial cells
Human bronchial epithelial cells were obtained from lung
resections performed for non-neoplastic conditions and cultured
as previously described [23,24]. The collection and processing of
human cells was approved by the Gaslini Institute’s ethics
committee. Briefly, bronchial epithelial cells were detached by
overnight digestion with protease XIV (Sigma, St. Louis, MO,
USA) and cultured on flasks in a serum-free culture medium
consisting of a 1:1 mixture of LHC9 (Invitrogen s.r.l., Milan,
Italy), and RPMI 1640 (Euroclone, Paington, Devon, UK). To
obtain polarized epithelia, cells were plated at high density
(2.5610
6 cells/cm
2) on Transwell porous supports (Corning
Costar, Cambridge, MA, USA). After 24 h, the serum free
medium was replaced with an enriched mixture containing
DMEM/Ham’s F12 (1:1) plus 2% FCS (Invitrogen) and various
hormones and supplements [23,24]. This medium allows the
generation of differentiated epithelia with high electrical
resistance, resembling the airway epithelium in vivo. Cell
differentiation was monitored by measuring daily transepithelial
electrical resistance and potential difference with an epithelial
voltmeter (World Precision Instruments, Sarasota, FL, USA).
Twenty ng/ml of hrIL-12 or medium alone were added to apical
and basolateral medium 8 days after plating, when the electrical
resistance was 800–1000 xcm
2 and the potential difference was
between 240 and 250 mV. Cells were subsequently cultured 24
to 48 h.
Short-circuit current measurements
Snapwell inserts carrying differentiated monolayers of bronchial
epithelial cells were mounted in a self-contained Ussing chamber
system (Vertical diffusion chamber; Corning Life Sciences) 8 days
after cell plating. Where needed, IL-12 (20 ng/ml) was applied in
the culture medium (apical and basolateral) for 24 hours before
Ussing chamber experiments were performed. The apical and
basolateral chambers contained identical solutions (in mM): 126
NaCl, 0.38 KH2PO4, 2.1 K2HPO4, 1 MgSO4, 1 CaCl2,2 4
NaHCO3 and 10 glucose (Sigma). During experiments, solutions
in both chambers were continuously bubbled with a mixture of 5%
CO2/95% air and all measurements were done at 37uC. Cells
were sequentially incubated with amiloride (10 mM, apical
solution) to inhibit the epithelial sodium channel (ENaC), the
cAMP-elevating agent forskolin (20 mM, apical and basolateral
solution) to activate CFTR, and UTP (100 mM, apical solution) to
trigger the activation of Ca
2+-dependent Cl
2 channels [25,26]. All
of these reagents were from Sigma. The apical and basolateral
chambers were connected to a DVC-1000 voltage clamp amplifier
(World Precision Instruments, Inc., Sarasota, FL) using Ag/AgCl
electrodes and 1 M KCl agar bridges. Short circuit currents,
reflecting transepithelial ion transport, were digitized using a
PowerLab 4/25 data acquisition system.
ELISA
Culture supernatants were tested in triplicate using the human
twenty seven cytokine Bio-Plex Assay (Bio-Rad Laboratories, Inc.,
CA, USA).
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Analysis of correlations between tumor stage and IL-12Rb2
immunostaining was carried out using Fisher’s exact test with
99% confidence interval. Differences vessel numbers or
cytokine concentrations were evaluated by Student’s t test.
Differences in tumor volume were calculated using Mann-Whitney
test comparing two independent samples, with 99% confidence
interval.
All statistical tests were two tailed. A P value lower than 0.05
was considered statistically significant.
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